BeyondSpring is trading at $0.56, up 6.94%, amid biotech-sector strength, the clearest available explanation for the move.
- Biotech ETF XBI was up 2.10%.
- No new company-specific announcement explaining the October 21 rise surfaced in the search; trading volume and current activity level were unavailable.
- BeyondSpring’s recent FDA rejection of plinabulin was reported as having triggered a sharp decline, not today’s rebound.